Abstract. Epigenetics serve a key role in peripheral T cell lymphoma (PTCL). The purpose of the present study was to investigate the clinical significance of enhancer of zeste homolog 2 (EZH2) and histone deacetylase 1 and 2 (HDAC1/2) expression in PTCL. A total of 82 patients were enrolled in the present study, including 43 with PTCL not otherwise specified (PTCL-NOS), 10 with angioimmunoblastic T-cell lymphoma (AITL), 14 with natural killer/T-cell lymphoma (NK/TCL) and 15 with anaplastic large cell lymphoma (ALCL). EZH2 and HDAC1/2 expression was detected by immunohistochemistry and any correlations between them were evaluated. Additionally, any correlations between EZH2 or HDAC1/2 expression and a number of clinicopathological characteristics were analyzed, and survival curves were created. Results revealed that 55.8% of patients with PTCL-NOS, 57.1% of patients with NK/TCL, 86.7% of patients ALCL and 50% of patients with AITL highly expressed HDAC1. Furthermore, 58.1% of patients with PTCL-NOS, 57.1% of patients with NK/TCL, 53.3% of patients with ALCL and 60% of patients with AITL highly expressed HDAC2. Additionally, 67.5% of patients with PTCL-NOS, 50% of patients with NK/TCL, 73.3% of patients with ALCL and 60% of patients with AITL highly expressed EZH2. EZH2 expression was significantly correlated with the presence of B symptoms, elevated LDH and elevated β2 microglobulin (B2M; P<0.05), and HDAC2 expression was significantly correlated with sex, advanced clinical stages, high international prognostic index scores and elevated B2M levels (P<0.05) in all the patients with PTCL. However, different subtypes of PTCL are correlated with different clinical characteristics. Patients with PTCL highly expressing EZH2 or HDAC2 exhibit a poorer overall survival rate. In conclusion, EZH2 and HDAC1/2 were frequently upregulated in patients with PTCL, and the patients with a higher EZH2 and HDAC2 expression usually exhibited a poorer survival rate. Therefore, EZH2 and HDAC2 may be prognostic markers in patients with PTCL, particularly in those with PTCL-NOS.
Introduction
Peripheral T cell lymphoma (PTCL) is a heterogeneous disease that accounts for 20-30% of all lymphomas in Asia (1) (2) (3) . According to the World Health Organization classification (2008) (4), PTCL consists of 22 different subtypes of T-cell and NK-cell lymphomas (5, 6) . The majority of patients with PTCL experience an aggressive disease process with a poor survival when treated with frontline therapies, and there are currently few effective treatment options. Therefore, PTCL urgently requires further research and novel treatment options in order to improve the survival of affected patients.
Epigenetics have been receiving increasing attention with respect to tumor development. Aberrant epigenetic dysregulations, including DNA methylation, histone modification, chromatin remodeling, genetic imprinting and random chromosome (X) inactivation, serve key functions in tumorigenesis. Until now, several inhibitors of histone deacetylases (HDACs), including vorinostat, panobinostat and belinostat have been reported to possess significant clinical value (7) . The balance between histone acetylation and deacetylation is regulated through the opposing family of enzymes (8) , histone acetylases. HDACs are critical for gene transcription and for the functions of various cellular proteins (9) . The initiation and progression of a variety of tumor types have also been demonstrated to be associated with histone acetylation and deacetylation (10) . Increased expression
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of HDACs reduces histone acetylation, which is widely known to occur in cancer. To date, 18 members of the HDAC family have been identified and may be categorized into four classes according to their homology, subcellular localization and enzyme reactions (11) . Class I HDACs include HDACs 1, 2, 3 and 8, which are primarily responsible for regulating the acetylation of histones. HDACs enhance the interactions between histones and negatively-charged DNA by restoring the positive charge, which results in the stabilization of chromatin conformations, thereby inhibiting gene expression, particularly that of tumor suppressor genes. HDACs are overexpressed in solid tumors and hematopoietic malignancies, and contribute to disease progression and a poor prognosis (12) (13) (14) (15) (16) (17) (18) (19) . However, studies regarding the association between the HDAC expression and the prognosis or clinicopathological characteristics in PTCL are rare.
Aberrant histone methylation also serves an important role in tumorigenesis. Polycomb repressive complex 2 (PRC2), existing in distinct multiprotein complexes that bind to and modify the chromatin of target genes, methylates lysine-27 of histone H3 (H3K27) (20) . PRC2 primarily consists of embryonic ectoderm development, suppressor of zeste homolog 12, enhancer of zest homolog 2 (EZH2) and RBAP48/RBBP4 (21) . H3K27 methylation may lead to inhibition of gene expression through transcriptional repression (22) . EZH2, as a catalytic subunit of PRC2, serves a key role in the epigenetic silencing of target genes (23) . Previous studies have revealed that the upregulation of EZH2 is associated with aggressive progression and a poor prognosis in a wide variety of tumor types (23) . Certain studies on the clinical significance of EZH2 in malignant B-cell lymphoma have been reported (24) . However, few studies regarding PTCL in general or its association with EZH2 have been reported.
The present study systematically studied the potential associations between HDAC or EZH2 expression and prognosis in PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), natural killer/T-cell lymphoma (NK/TCL) and anaplastic large cell lymphoma (ALCL).
Materials and methods

Patient characteristics.
A total of 82 patients with previously untreated PTCL diagnosed by a pathologist were enrolled in the present study at Tianjin Medical University Cancer Hospital (Tianjin, China) between January 2007 and December 2015. The median age of all the evaluated patients was 54 years (range, 17-80 years), with a male-to-female ratio of 1. Immunohistochemistry. Tissues were collected and fixed in 4% formaldehyde at room temperature overnight and immunohistochemical staining was performed on 4-µm formalin-fixed paraffin-embedded sections, which were provided by the Pathology Department at The Tianjin Medical University Cancer Hospital. Tissue sections were dewaxed in xylene at 60˚C for 40 min, rehydrated with graded alcohol and rinsed with water. Briefly, 10 mM citrate buffer (pH 6.0) was used for antigen retrieval at 120˚C for 2.5 min followed by cooling to room temperature. Freshly prepared 3% hydrogen peroxide in methanol solution (V 30% hydrogen peroxide : V methanol =1:9) was added and tissues were incubated in the dark at room temperature for 20 min to eliminate endogenous peroxidase activity. Following rinsing with phosphate-buffered saline, the slides were incubated with polyclonal rabbit anti-HDAC1 (catalog no. BS6485; 1:100 dilution; Bioworld Technology, Inc., St. Louis Park, MN, USA), polyclonal rabbit anti-HDAC2 (catalog no. 12922-3-AP; 1:200 dilution; ProteinTech Group, Inc., Chicago, IL, USA) and polyclonal rabbit anti-EZH2 (catalog no. BS90776; 1:50 dilution; Bioworld Technology, Inc.) primary antibodies overnight at 4˚C. Sections were subsequently incubated with unconjugated anti-rabbit IgG Ab secondary antibody (catalog no. TA130015; 1:200 dilution; OriGene Technologies, Inc., Beijing, China) at 37˚C for 90 min, and were stained with hematoxylin for 3 min at room temperature. Negative controls were included by omitting the primary antibody. Tissues were imaged at x200 and x400 magnification with an optical microscope. Prostate and breast cancer tissues were used as positive controls as these tissues exhibit a high expression of HDAC1/2 and EZH2, respectively.
Evaluation of immunohistochemistry.
Antibodies against HDAC1/2 and EZH2 proteins were used to stain the nuclei EZH2, enhancer of zeste homolog 2; HDAC, histone deacetylase; PTCL, peripheral T cell lymphoma; PTCL-NOS, PTCL not otherwise specified; AICL, angioimmunoblastic T-cell lymphoma; ALCL; anaplastic large cell lymphoma; NK/TCL, natural killer/T-cell.
of lymphoma cells. Immunohistochemical staining was interpreted based upon the following two parameters: The staining intensity and the proportion of positively-stained cells. The number of positively-stained cells was scored as follows: 0, <5%; 1, >5% and ≤25%; 2, >25% and ≤50%; and 3, >50% positive cells. The intensity of positivity was scored as follows: 0, no positivity; 1, weak positivity; 2, moderate positivity; and 3, strong positivity. The values of the two scores were then multiplied with a score of <3 as the low expression group and a score of ≥3 as the high expression group.
Survival and statistical analysis. IBM SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Associations between HDAC1, HDAC2 or EZH2 expression and clinicopathological characteristics were analyzed using the a χ 2 test. Correlations between EZH2 and HDAC1/2 expression were analyzed using Phi coefficient analysis. Univariate OS rates were obtained using the Kaplan-Meier method and the log-rank test. OS periods were defined as the intervals between primary surgery and the last follow-up visit or mortality from any cause. The Cox proportional hazards model was used to evaluate the associations between clinicopathological factors and survival rates. The hazard ratio (HR) and associated 95% confidence interval (CI) were calculated for each variable. P<0.05 was considered to indicate a statistically significant difference.
Results
Correlation between EZH2 and HDAC1 and HDAC2 expression in PTCL.
The percentages of patients expressing EZH2, HDAC1 and HDAC2 were 64.6% (53/82), 61.0% (50/82) and 57.3% (47/82), respectively, (staining intensity score ≥3). Fig. 1 . Table II . Correlations between EZH2 and HDAC1/2 in four subtypes of PTCL. Phi coefficient analysis demonstrated that EZH2 expression was correlated with HDAC1 and HDAC2 expression (r=0.297 and r=0.306, respectively; P<0.01). Of the four subtypes, the correlation between EZH2 and HDAC2 expression was only observed in patients with PTCL-NOS (r=0.517; P<0.01). However, the correlation between EZH2 and HDAC1 was observed in patients with ALCL (r=0.577; P<0.05) (Table II) .
Association between EZH2, HDAC1 and HDAC2 expression and clinicopathological characteristics in PTCL.
In patients with PTCL, high EZH2 expression was significantly associated with the presence of B symptoms (P=0.022), elevated LDH levels (P=0.029), elevated B2M levels (P=0.014) and a high white blood cell count (P=0.010). High HDAC2 expression was significantly associated with sex (P=0.016), Marrow involvement (P=0.07), advanced clinical stage (P=0.005), a Table III . Correlations between EZH2/HDAC1/2 expression and the clinicopathological characteristics in PTCL. high IPI score (P=0.032) and elevated B2M levels (P=0.037). High HDAC1 expression was only significantly associated with a high IPI score (P=0.043; Table III ).
In PTCL-NOS patients, high EZH2 expression was significantly associated with advanced clinical stage (P=0.021) and high Ki-67 expression (P=0.021), while overexpression of HDAC1 was significantly associated with advanced clinical stage (P=0.029), elevated B2M levels (P=0.004) and elevated LDH levels (P=0.028). The overexpression of HDAC2 was significantly associated with advanced clinical stage (P=0.000; Table IV ). However, the associations between high expression and low expression of these proteins were insignificant in NK/TCL patients (Table V) .
Correlation between EZH2, HDAC1 and HDAC2, and survival. The median follow-up period was 45.8 months (range, 4.7-109.3 months). The 3-year OS rates of the high and low EZH2 expression PTCL groups were 28.0 and 40.2%, respectively (P=0.012). The 3-year OS rates of the high and low HDAC2 expression groups were 16.5 and 57.0%, respectively (P<0.01). However, the 3-year OS rates of the high and low HDAC1 expression groups exhibited had no significant differences (P>0.05). Table IV . Correlations between the EZH2/HDAC1/2 expression and the clinicopathological characteristics in PTCL-NOS. The OS rate was significantly poorer in patients with PTCL exhibiting high EZH2 and HDAC2 expression compared with those exhibiting low expression (P<0.05; Fig. 2 ). This finding was also observed in the PTCL-NOS subtype (P<0.05; Fig. 3 ).
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Multivariate analysis of age, sex, Ki-67 expression, IPI, clinical stage, B symptoms, marrow involvement, LDH and B2M levels during diagnosis was performed. The results revealed that advanced clinical stage (P=0.024; HR, 0.360; 95% CI, 0.148-0.875) and HDAC2 expression (P=0.027; HR, 0.462; 95% CI, 0.234-0.914), but not EZH2 and HDAC1 expression, were significantly associated with a poor OS, indicating that HDAC2 may be an independent prognostic factor in PTCL (Table VI) . Similar results were observed in PTCL-NOS (Table VII) .
Discussion
Tumorigenesis involves gene mutation and epigenetics, which contribute to the heritable alteration of cellular biological functions. Epigenetics include DNA methylation, histone acetylation, chromatin remodeling, genetic imprinting and random chromosome (X) inactivation. In particular, histone Table V . Correlations between the EZH2/HDAC1/2 expression and the clinicopathological characteristics in NK/TCL. The present study demonstrated that the patients with B symptoms, elevated LDH or β2-MG levels exhibited high EZH2 expression in their PTCL tissues, and that these factors led to a poorer OS (P<0.05). Based upon analysis of the pathological subtypes of PTCL, high EZH2 expression was significantly associated with advanced clinical stage and high Ki-67 expression in PTCL-NOS. The enzymatic hyperactivity of EZH2 has previously been observed in a variety of hematological malignancies, including diffused large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma (27) , T-lymphoblastic lymphoma (28) and adult T-cell leukemia/lymphoma (29) . The results of the present study were consistent with those of previous reports that EZH2 expression is also associated with an aggressive clinical outcome (30) . The results of the present study suggested that EZH2 may serve as a target for anticancer therapy in PTCL and that further research on the mechanisms of EZH2 is warranted.
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Furthermore, the present study revealed that HDAC expression was associated with EZH2 expression in PTCL, which was consistent with the results of a previous study (31) . HDAC1, HDAC2 and EZH2 serve important roles in DNA repair by regulating the dynamic balance between H3K27ac and H3K27me3. This balance may be disturbed by DNA damage, resulting in tumorigenesis (31,32).
The catalysis of HDAC1 and HDAC2 contributes to the reduction in H3K27ac levels, resulting in further methylation of H3K27 by EZH2. C-myc, an important transcription regulatory factor, regulates >70% of gene expression, including that of EZH2. C-myc upregulates the expression of EZH2 by modulating the special microRNAs in B-cell lymphoma cells (33) . C-myc is overexpressed in several subsets of T-cell lymphoma (30) . Therefore, several unknown associations may exist between expression of HDACs and EZH2 in PTCL.
HDACs render the gene expression profiling aberrant by deacetylating either histone or transcription factors (34) (35) (36) . The US Food and Drug Administration has approved four HDAC inhibitors (HDACIs) for the treatment of cutaneous T-cell lymphoma, and the clinical application of HDACIs in other subtypes of T-cell lymphoma has received increasing attention. Based upon the results of clinical trials, three HDACIs have received conditional marketing authorization for the treatment of adult patients with relapsed or refractory aggressive PTCL. However, the clinical significance of HDAC expression in PTCL is poorly understood.
The present study demonstrated that high expression of HDAC2 frequently occurred in PTCL patients with adverse clinicopathological characteristics, including advanced clinical stage, high IPI score and elevated B2M (P<0.05). However, for PTCL subtype analysis, high HDAC2 expression was only associated with the clinical stage in patients with PTCL-NOS, and was only associated with patient sex in patients with NK/TCL. In addition, in patients with the PTCL-NOS subtype, high HDAC2 expression resulted in a shorter OS time than that in those exhibiting a low HDAC2 expression (P<0.05). This association was observed in all PTCL patients. According to the results of the present study, HDAC2 may be a possible prognostic marker in patients with PTCL, particularly in those with the PTCL-NOS subtype. This phenomenon was not observed in the other subtypes of PTCL. One possible reason for this is the small number of patients enrolled in the present study (37, 38) . Therefore, further studies on assessing the clinical significance of HDAC2 were required in all PTCL subtypes.
In conclusion, the present study observed that PTCL patients with high expression of EZH2 and HDAC2 usually exhibit a poorer prognosis, and that HDAC2 may be a prognostic marker in PTCL, particularly for patients with the PTCL-NOS subtype.
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